Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Arbutus Biopharma CorporationNASDAQ: ABUS
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to 94.4%
Operating margin was 94.4% in Q1 FY2026, up 2059.2 pp from a year earlier. On a trailing-twelve-month basis it was 80.8%, up 1511.6 pp year over year. Over 3 fiscal years it narrowed by 24.3 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of 98.6% for the fiscal year ending Dec 2026, up from -192.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 94.4%+821.7 pp QoQ
- Last fiscal yearDec 2025
- -192.1%+1044.7 pp YoY
- LTMMar 2026
- 80.8%+1511.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -192.1%
- Year-over-year change
- +1044.7pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -192.1% | +1044.7pp |
| FY2024 | 2024-12-31 | -1236.7% | -806.2pp |
| FY2023 | 2023-12-31 | -430.5% | -262.8pp |
| FY2022 | 2022-12-31 | -167.8% | +501.4pp |
| FY2021 | 2021-12-31 | -669.1% | — |
Operating Margin vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 operating margin of 80.8% is the highest of the 7 companies compared; the peer median is -122.1%.
- Its year-over-year change of +1511.6 pp is the 2nd highest of 6, against a peer median of +71.2 pp.
- Over three fiscal years its change of -24.3 pp compares with a peer median of -71.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 80.8% | +1511.6 pp | -24.3 pp | |
| LTM Jun 2026 | 20.8% | +28.1 pp | +89.2 pp | |
| LTM Mar 2026 | -19.1% | +119.8 pp | — | |
| LTM Mar 2026 | -87.2% | +71.2 pp | +13.1 pp | |
| LTM Sep 2026 | -156.9% | -168.7 pp | -71.7 pp | |
| LTM Mar 2026 | -704.9% | +2394.8 pp | -734.2 pp | |
| LTM Mar 2026 | -9396.6% | — | -15774.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ABUS) | -122.1% | +71.2 pp | -71.7 pp | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.99M | 39.02M | 18.14M | 6.17M | 14.08M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 363K |
| Gross Profit | 10.99M | 39.02M | 18.14M | 6.17M | 13.72M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% |
| Research & Development | 65.5M | 84.41M | 73.7M | 54.04M | 25.24M |
| Selling, General & Admin | 17.14M | 17.83M | 22.48M | 22.11M | 15.89M |
| Operating Expenses | 84.51M | 104.48M | 96.24M | 82.49M | 40.77M |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| EBITDA | (71.64M) | (61.86M) | (70.99M) | (68.4M) | (33.04M) |
| EBITDA Margin | -652.0% | -158.5% | -391.3% | -1108.5% | -234.6% |
| Operating Income | (73.52M) | (65.46M) | (78.1M) | (76.32M) | (27.05M) |
| Operating Margin | -669.1% | -167.8% | -430.5% | -1236.7% | -192.1% |
| Interest Income | 127K | 2.19M | 5.69M | 6.59M | 4.07M |
| Interest Expense | 2.86M | 1.73M | 459K | 137K | 97K |
| Other Income / Expenses | (2.73M) | 444K | 5.25M | 6.4M | (6.45M) |
| Income Before Tax | (76.25M) | (65.01M) | (72.85M) | (69.92M) | (33.5M) |
| Pre-Tax Margin | -693.9% | -166.6% | -401.6% | -1133.0% | -237.9% |
| Income Tax Expense | 0 | 4.44M | 0 | 0 | 0 |
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Net Margin | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| EPS (Basic) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| EPS (Diluted) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| Weighted Avg Shares | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
| Weighted Avg Shares (Diluted) | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.